Publication Date: 1/6/2010
- July 27, 2009 With American Indians three times more likely to be diagnosed with diabetes than any other group, a handful of educators are ready to fan out across New Mexico and neighboring states to introduce a new school curriculum aimed at tackling the disease among children. [Story at The Salt Lake Tribune: New program to tackle diabetes among young Indians.]
- July 20, 2009 Sanofi-aventis has released a statement by a board of experts regarding the potential link of Lantus with increased cancer risk. Studies published by the European Association for the Study of Diabetes observed that Lantus increases the risk of cancer in diabetics taking the drug. The studies, carried out on 127,000 patients in four European countries found that out of every 100 patients using Lantus for about 1 1/2 years, one additional person developed cancer. But the FDA was not convinced with the study as patients were not studied long enough to substantiate the risk. And the experts have come to the conclusion that all the four recent publications had significant methodological limitations and shortcomings, thus making the results inconclusive. [Story at Seeking Alpha: Lantus Cancer Risk Inconclusive: Good News for Sanofi-Aventis? Press release from s-a at Expert Statement Issued about Lantus Following Recent Publications in Diabetologia - Leading international experts conclude that these analyses present inconclusive and conflicting data; Expert report at sanofi-aventis website; commentary by the Medical Director of Diabetes Monitor at Insulin and cancer.]
- July 13, 2009 Medtronic Diabetes is recalling Quick-set infusion sets that have lot numbers starting with the number "8". These infusion sets are used with MiniMed Paradigm® insulin pumps. This decision was made because an estimated 2% of "Lot 8" Quick-set infusion sets may not work properly. [See Medtronic MiniMed's website: Medtronic Diabetes is recalling Quick-set infusion sets that have lot numbers starting with the number "8".]
- July 6, 2009 Both AstraZeneca's saxagliptin (Onglyza) and Novo Nordisk's liraglutide (Victoza) have won regulatory approval for sale in the EU. [Story at The In Vivo Blog: Novo Hopes Victoza’s EU Clearance Bodes Well for US.]
